subscribeSubscribe
price-trendAsk Us
Takeda announces voluntary withdrawal of lung cancer therapy

Takeda announces voluntary withdrawal of lung cancer therapy
HEALTH ET
03 Oct 2023
Share Share
Takeda Provides Update on EXKIVITY® (mobocertinib)

Takeda Provides Update on EXKIVITY® (mobocertinib)
BUSINESSWIRE
02 Oct 2023
Share Share
Takeda`s Exkivity, a rival to J&J, fails in lung cancer trial

Takeda`s Exkivity, a rival to J&J, fails in lung cancer trial
Angus Liu FIERCE PHARMA
01 Aug 2023
Share Share
FoundationOne®Liquid CDx Receives FDA-Approval as a Companion for EXKIVITY

FoundationOne®Liquid CDx Receives FDA-Approval as a Companion for EXKIVITY
BUSINESSWIRE
04 May 2023
Share Share
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China
BUSINESSWIRE
11 Jan 2023
Share Share
NHS grants fast-track access to Takeda`s lung cancer drug Exkivity

NHS grants fast-track access to Takeda`s lung cancer drug Exkivity
K. Dunleavy PHARMAPHORUM
22 Mar 2022
Share Share
US FDA approval tracker: September

US FDA approval tracker: September
Joanne Fagg EVALUATE
01 Oct 2021
Share Share
U.S. FDA approves Takeda`s lung cancer therapy

U.S. FDA approves Takeda`s lung cancer therapy
REUTERS
17 Sep 2021
Share Share
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer
PRESS RELEASE
18 Sep 2020
Share Share